The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches

International Journal of Molecular Sciences

Rossella Manfredini¹  Vincenzo Nasillo²  Enrico Tagliafico²  Giovanni Riva²  Tommaso Trenti²  Patrizia Comoli³  Sabrina Basso³  Giovanna Leonardi⁴  Roberto Marasca⁴  Angela Cuoghi⁴  Francesca Bettelli⁴  Francesca Donatelli⁴  Davide Giusti⁴  Mario Luppi⁴  Corrado Colasante⁴  Andrea Gilioli⁴  Leonardo Potenza⁴  Paola Bresciani⁴  Andrea Messerotti⁴  Fabio Forghieri⁴  Patrizia Barozzi⁴  Ivana Lagreca⁴  Elisabetta Colaci⁴  Monica Morselli⁴  Daniela Vallerini⁴  Valeria Pioli⁴  Ilaria Castelli⁴  Monica Maccaferri⁴  Ambra Paolini⁴ 

[1] Centre for Regenerative Medicine “S. Ferrari”, University of Modena and Reggio Emilia, 41125 Modena, Italy;Diagnostic Hematology and Clinical Genomics, Department of Laboratory Medicine and Pathology, AUSL/AOU Modena, 41124 Modena, Italy;Pediatric Hematology/Oncology Unit and Cell Factory, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, 27100 Pavia, Italy;Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy;

关键词: MGUS;    multiple myeloma;    plasma cells;    T cell immunity;    tumor microenvironment;    immunotherapy;   

DOI  :  10.3390/ijms23095242

来源: DOAJ

【 摘 要 】

Multiple Myeloma (MM) is a malignant growth of clonal plasma cells, typically arising from asymptomatic precursor conditions, namely monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). Profound immunological dysfunctions and cytokine deregulation are known to characterize the evolution of the disease, allowing immune escape and proliferation of neoplastic plasma cells. In the past decades, several studies have shown that the immune system can recognize MGUS and MM clonal cells, suggesting that anti-myeloma T cell immunity could be harnessed for therapeutic purposes. In line with this notion, chimeric antigen receptor T cell (CAR-T) therapy is emerging as a novel treatment in MM, especially in the relapsed/refractory disease setting. In this review, we focus on the pivotal contribution of T cell impairment in the immunopathogenesis of plasma cell dyscrasias and, in particular, in the disease progression from MGUS to SMM and MM, highlighting the potentials of T cell-based immunotherapeutic approaches in these settings.

【 授权许可】

Unknown